Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pulmagen Therapeutics
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of COPD that has been symptomatic for at least 2 years
The subject has moderate to severe COPD, as defined by the American Thoracic Society and the European Respiratory Society
The subject can produce an adequate sputum specimen after induction
The subject has a history of ≥ 10-pack years of cigarette smoking
The subject has either a ≤15% increase or ≤200 ml increase in FEV1 from pre-dose following a fixed dose of bronchodilator therapy
The subject is able to provide written, informed consent to participate
You may not be if
The subject has experienced a respiratory tract infection and/or an exacerbation of COPD within 30 days
The subject uses systemic corticosteroids (oral or parenteral)
The subject has received long term oxygen therapy within 30 days
The subject has a previous history or diagnosis of asthma
The subject has a chest x-ray within the past 12 months which is diagnostic of an active or clinically significant disease other than COPD
The subject has a history or presence of active tuberculosis, cystic fibrosis, bronchiectasis, lung cancer or sarcoidosis or any other clinically important lung diseases
The subject has had radiation or chemotherapy within the previous 12 months
The subject has a history of anaphylaxis associated with medicinal products
The subject is pregnant, intends to become pregnant, or is breast feeding
The subject's alcohol intake is excessive.
The subject participated in another study (for a marketed drug) within 3 months before the start of this study or (for an investigational drug) within 4 months before the start of this study.
Clareo Health | Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
